ASND Ascendis Pharma A/S Stock Quote

ASND [NASD]

Index	-	P/E	-	EPS (ttm)	-8.86	Insider Own	0.03%	Shs Outstand	52.72M	Perf Week	-9.59%
Market Cap	7.90B	Forward P/E	-	EPS next Y	-6.22	Insider Trans	0.00%	Shs Float	6.00M	Perf Month	-5.10%
Income	-438.80M	PEG	-	EPS next Q	-1.55	Inst Own	-	Short Float	36.87%	Perf Quarter	-14.93%
Sales	10.90M	P/S	724.88	EPS this Y	-48.00%	Inst Trans	1.40%	Short Ratio	11.69	Perf Half Y	-0.42%
Book/sh	21.98	P/B	6.53	EPS next Y	9.50%	ROA	-49.60%	Target Price	191.77	Perf Year	7.85%
Cash/sh	20.55	P/C	6.98	EPS next 5Y	24.00%	ROE	-56.00%	52W Range	92.00 - 183.98	Perf YTD	-13.99%
Dividend	-	P/FCF	-	EPS past 5Y	-61.90%	ROI	-35.70%	52W High	-22.03%	Beta	0.79
Dividend %	-	Quick Ratio	14.80	Sales past 5Y	-0.90%	Gross Margin	-	52W Low	55.92%	ATR	6.61
Employees	330	Current Ratio	14.80	Sales Q/Q	27.30%	Oper. Margin	-	RSI (14)	35.98	Volatility	4.85% 4.12%
Optionable	Yes	Debt/Eq	0.03	EPS Q/Q	-337.60%	Profit Margin	-	Rel Volume	3.19	Prev Close	152.90
Shortable	Yes	LT Debt/Eq	0.03	Earnings	-	Payout	-	Avg Volume	189.15K	Price	143.45
Recom	1.50	SMA20	-7.73%	SMA50	-10.63%	SMA200	-6.72%	Volume	577,520	Change	-6.18%

Dec-17-20

Initiated

Berenberg

Buy

$216

Sep-14-20

Resumed

JP Morgan

Overweight

$160

Mar-20-20

Initiated

Oppenheimer

Outperform

$199

Oct-11-19

Initiated

Morgan Stanley

Overweight

$128

Mar-25-19

Initiated

Evercore ISI

Outperform

Jan-24-19

Upgrade

Leerink Partners

Mkt Perform → Outperform

Jan-24-19

Initiated

Cantor Fitzgerald

Overweight

$102

Jun-26-18

Initiated

Stifel

Buy

$85

Apr-02-18

Reiterated

Leerink Partners

Mkt Perform

$37 → $64

May-11-17

Initiated

JP Morgan

Overweight

$36

Mar-09-17

Downgrade

Leerink Partners

Outperform → Mkt Perform

Feb-09-17

Initiated

Credit Suisse

Outperform

$28

Sep-26-16

Initiated

Wedbush

Outperform

$34

Mar-04-21 04:05PM	Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10 GlobeNewswire -6.18%
Feb-26-21 07:05AM	Ascendis Pharma A/S Announces New Outgrow GHD Educational Resource to Support Rare Disease Day 2021 GlobeNewswire
Feb-18-21 04:05PM	Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire -5.77%
Jan-14-21 08:29AM	New Strong Sell Stocks for January 14th Zacks
Jan-13-21 11:02AM	New Strong Sell Stocks for January 13th Zacks
Jan-10-21 07:04PM	Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-08-21 10:06PM	VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China PR Newswire
07:39PM	Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals GlobeNewswire
Jan-04-21 07:05AM	Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-30-20 04:05PM	Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon TLR7/8 Agonist Clinical Program GlobeNewswire
08:47AM	Implied Volatility Surging for Ascendis Pharma (ASND) Stock Options Zacks
Dec-14-20 04:05PM	Ascendis Pharma A/S Announces Planned Board Transition GlobeNewswire
Nov-25-20 07:05AM	Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference GlobeNewswire
Nov-15-20 07:20AM	Earnings Update: Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts Simply Wall St.
Nov-11-20 05:30PM	Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20 GlobeNewswire
04:24PM	Recap: Ascendis Pharma Q3 Earnings Benzinga
04:01PM	Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results GlobeNewswire
07:38AM	The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga
Nov-10-20 08:40AM	Why Earnings Season Could Be Great for Ascendis (ASND) Zacks
Nov-04-20 10:12AM	Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards? Zacks +5.01%
10:09AM	Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-03-20 07:05AM	Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases GlobeNewswire
Nov-02-20 04:05PM	Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11 GlobeNewswire
Oct-23-20 08:05AM	Ascendis Pharma A/S Receives Orphan Designation for TransCon PTH for Treatment of Hypoparathyroidism in Europe GlobeNewswire
Oct-21-20 05:51PM	Ascendis Pharma A/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences GlobeNewswire
Oct-08-20 06:40PM	Free Stock Pick From Insider Monkeys Monthly Newsletter Insider Monkey
Sep-29-20 11:04AM	Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH Zacks
Sep-28-20 07:00PM	Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon PTH in Adult Hypoparathyroidism GlobeNewswire
Sep-23-20 04:05PM	Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon hGH for Pediatric Growth Hormone Deficiency in Japan GlobeNewswire
Sep-15-20 05:45PM	Ascendis Pharma A/S Announces Support for Childrens Growth Awareness Week and Day 2020 GlobeNewswire
08:30AM	Is Ascendis Pharma A/S (ASND) Going to Burn These Hedge Funds? Insider Monkey
Sep-11-20 07:05AM	Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference GlobeNewswire
Sep-10-20 07:05AM	Ascendis Pharma A/S Announces Presentations for TransCon PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting GlobeNewswire
Sep-08-20 04:44PM	Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon hGH for Treatment of Pediatric Growth Hormone Deficiency GlobeNewswire
Sep-04-20 08:30AM	Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon hGH for Pediatric Growth Hormone Deficiency (GHD) GlobeNewswire
07:05AM	Ascendis Pharma A/S Announces Presentations for TransCon PTH and Hypoparathyroidism at 22nd European Congress of Endocrinology GlobeNewswire
Sep-02-20 04:05PM	Ascendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare Conference GlobeNewswire
Aug-27-20 10:00PM	Ascendis Pharma A/S (ASND) Q2 2020 Earnings Call Transcript Motley Fool
04:24PM	Ascendis Pharma: Q2 Earnings Insights Benzinga
04:01PM	Ascendis Pharma A/S Reports Second Quarter 2020 Financial Results and Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial GlobeNewswire
Aug-21-20 09:48AM	The Ascendis Pharma (NASDAQ:ASND) Share Price Is Up 646% And Shareholders Are Delighted Simply Wall St.
Aug-13-20 04:01PM	Ascendis Pharma A/S Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 27 GlobeNewswire
12:48PM	Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU Zacks
Aug-12-20 07:05AM	Ascendis Pharma A/S Receives Orphan Designation for TransCon CNP for the Treatment of Achondroplasia in Europe GlobeNewswire
Aug-04-20 08:30AM	Ascendis Pharma A/S Announces Upcoming Investor Presentations in August GlobeNewswire
Jul-24-20 09:47AM	Why Ascendis Pharma (ASND) Stock is a Compelling Investment Case Insider Monkey
Jul-10-20 08:49PM	Did Hedge Funds Make The Right Call On Ascendis Pharma A/S (ASND) ? Insider Monkey
Jul-07-20 10:11PM	Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs GlobeNewswire
Jul-06-20 12:58PM	Ascendis Pharma A/S Announces Proposed Public Offering of ADSs GlobeNewswire
09:25AM	Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan GlobeNewswire
Jun-29-20 11:44AM	Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD Zacks
Jun-26-20 08:29AM	Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon hGH in Pediatric Growth Hormone Deficiency GlobeNewswire
Jun-22-20 08:30AM	Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 / at AACR Virtual Annual Meeting 2020 GlobeNewswire
Jun-10-20 12:27PM	Ascendis Pharma Clears Technical Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
Jun-08-20 08:15AM	Ascendis Pharma A/S Announces Participation in ENDO Online 2020 GlobeNewswire
Jun-03-20 03:46PM	Should You Avoid Ascendis Pharma A/S (ASND)? Insider Monkey
May-29-20 09:28PM	Merit Medical Reaches Deal With Starboard Value Barrons.com
May-22-20 06:14AM	Earnings Beat: Ascendis Pharma A/S (NASDAQ:ASND) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
May-19-20 04:01PM	Ascendis Pharma A/S Reports First Quarter 2020 Financial Results GlobeNewswire
02:30PM	Ascendis Pharma A/S to Host Earnings Call ACCESSWIRE
May-11-20 08:30AM	Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer GlobeNewswire
May-08-20 11:46AM	7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace
May-07-20 04:01PM	Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19 GlobeNewswire
Apr-21-20 06:01AM	Ascendis Pharma A/S (NASDAQ:ASND) Analysts Just Slashed This Year's Revenue Estimates By 12% Simply Wall St. -5.84%
Apr-19-20 04:00PM	Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon PTH as a Replacement Therapy for Hypoparathyroidism GlobeNewswire
Apr-16-20 09:40PM	Edited Transcript of ASND earnings conference call or presentation 1-Apr-20 8:30pm GMT Thomson Reuters StreetEvents
Apr-15-20 04:58PM	Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon hGH as Treatment for Growth Hormone Deficiency in the United States GlobeNewswire
Apr-01-20 04:01PM	Ascendis Pharma A/S Reports Full-Year 2019 Financial Results GlobeNewswire
Mar-25-20 04:01PM	Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1 GlobeNewswire
Mar-22-20 08:25PM	Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND) Insider Monkey
Mar-21-20 08:49AM	We're Hopeful That Ascendis Pharma (NASDAQ:ASND) Will Use Its Cash Wisely Simply Wall St.
Mar-17-20 12:00PM	Ascendis Pharma A/S (ASND) Moves to Buy: Rationale Behind the Upgrade Zacks
Feb-12-20 04:01PM	Ascendis Pharma A/S Announces Upcoming Investor Presentation in February GlobeNewswire
Feb-10-20 09:28AM	Alkermes (ALKS) to Report Q4 Earnings: What's in Store? Zacks
Feb-06-20 10:44AM	Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-04-20 11:28AM	Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter GuruFocus.com
Jan-21-20 05:21AM	Shareholders Are Raving About How The Ascendis Pharma (NASDAQ:ASND) Share Price Increased 554% Simply Wall St.
Jan-12-20 07:45PM	Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-09-20 04:00PM	Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-26-19 11:26AM	How Did Ascendis Pharma A/S (ASND) Compare Against Hedge Fund Darlings in 2019? Insider Monkey
Dec-06-19 11:57PM	Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Dec-04-19 12:42PM	Heres What Hedge Funds Think About Ascendis Pharma A/S (ASND) Insider Monkey
Nov-22-19 05:38AM	Ascendis Pharma A/S Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates Simply Wall St.
Nov-21-19 09:05AM	Top Ranked Momentum Stocks to Buy for November 21st Zacks
Nov-18-19 04:01PM	Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results GlobeNewswire
10:33AM	Top Ranked Momentum Stocks to Buy for November 18th Zacks
01:02AM	New Records and New Milestones Zacks
Nov-14-19 04:01PM	Ascendis Pharma Expands TransCon PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States GlobeNewswire
Nov-12-19 09:52AM	What's in Store for Helmerich & Payne (HP) in Q4 Earnings? Zacks
Nov-11-19 07:50AM	5 Biotech Stocks Set to Beat Q3 Earnings Estimates Zacks
Nov-08-19 04:02PM	Ascendis Pharma A/S Announces Upcoming Investor Presentation in November GlobeNewswire
Nov-06-19 04:02PM	Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon Technology in Oncology at SITC 2019 GlobeNewswire
Nov-05-19 11:50AM	CannTrust (CTST) to Report Q3 Earnings: What's in Store? Zacks
11:13AM	Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-04-19 06:30PM	Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18 GlobeNewswire
Oct-29-19 09:00AM	Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why Zacks
Oct-24-19 11:47AM	How to invest in biotech stocks like a Nobel Prize winner MarketWatch
Oct-21-19 04:04PM	Ascendis Pharma A/S Receives Orphan Designation for TransCon hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe GlobeNewswire
Oct-14-19 08:44PM	Heres What Hedge Funds Think About Ascendis Pharma A/S (ASND) Insider Monkey
Oct-01-19 03:50PM	Edited Transcript of ASND earnings conference call or presentation 28-Aug-19 8:30pm GMT Thomson Reuters StreetEvents

Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience